Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30728071 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL29737686 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| Uric Acid SCHEMBL28407297 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL932609 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL10997 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| Uric Acid SCHEMBL2786719 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL30537976 | 0.74 | ALDH1A1 (0.60) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL2837685 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| Uric Acid SCHEMBL30269772 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEXDH | |
| SCHEMBL31152019 | 0.72 | MAPT (0.52) | MAPTADORA2BGDAACHEXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| US-20160304520-A1 | An improved process for preparing Linagliptin and its key Intermediates | WOCKHARDT LTD (IN) | 2016-10-20 | — | — | US | claimed |
| EP-2935266-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | Mylan Laboratories Ltd. (IN) | 2015-10-28 | — | — | EP | claimed |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2015-10-22 | — | — | US | claimed |
| WO-2015004599-A1 | AN IMPROVED PROCESS FOR PREPARING LINAGLIPTIN AND ITS KEY INTERMEDIATES | WOCKHARDT LIMITED (IN) | 2015-01-15 | — | — | WO | claimed |
| WO-2014097314-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2014-06-26 | — | — | WO | claimed |
| EP-2465859-A1 | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists | Life & Brain GmbH (DE) | 2012-06-20 | — | — | EP | claimed |
| WO-2012076974-A1 | 8-TRIAZOLYLXANTHINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | LIFE & BRAIN GMBH (DE) | 2012-06-14 | — | — | WO | claimed |
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-10-06 | — | — | US | claimed |
| CN-101809167-A | Methods of producing aptamers with improved off-rates | SOMALOGIC INC | 2010-08-18 | — | — | CN | claimed |
| US-20040132067-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2004-07-08 | — | — | US | claimed |
| US-20030054360-A1 | Method and apparatus for the automated generation of nucleic acid ligands | SOMALOGIC, INC. | 2003-03-20 | — | — | US | claimed |
| US-6482594-B2 | Made by exposing nucleic acid candidate sequences having photoreactive groups to the target molecule, irradiating complexes formed to crosslink, and separating the crosslinked complexes and amplifying to give the ligands | SOMALOGIC, INC. | 2002-11-19 | — | — | US | claimed |
| WO-2002077262-A2 | METHOD AND APPARATUS FOR THE AUTOMATED GENERATION OF NUCLEIC ACID LIGANDS | SOMALOGIC, INC. (US) | 2002-10-03 | — | — | WO | claimed |
| US-20020106652-A1 | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex | SOMALOGIC, INC. | 2002-08-08 | — | — | US | claimed |
| US-6001577-A | SCREENING FOR LIGANDS ASSOCIATED WITH A DISEASE BY DETECTING LIGAND THAT PHOTOCROSSLINKS TO TARGET WITH PHOTOREACTIVE GROUPS FROM CANDIDATE MIXTURE, REMOVING ANY NUCLEIC ACIDS WITH AFFINITIES NOT ASSOCIATED WITH DISEASE, AND AMPLIFYING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0736105-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIV RESEARCH CORP (US) | 1998-10-28 | — | — | EP | claimed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | claimed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245479-A1 | Method for Generating Aptamers with Improved Off-Rates | DDX1, DDX3X, DDX18 | MAPT 3254/4885ADORA2B 625/4885GDA 204/4885 |
| US-20160304520-A1 | An improved process for preparing Linagliptin and its key Intermediates | DPP4, LCT, DPP3 | MAPT 1535/4885ADORA2B 1797/4885GDA 1939/4885 |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DPP4, DPP3, DPP8 | MAPT 2289/4885ADORA2B 1759/4885GDA 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.